BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Jamie Hayden Von Roenn, MD

Robert H. Lurie Cancer Center

Intervention

rebimastat(drug)

Enrollment

59 enrolled

Eligibility

16 years · All sexes

Timeline

2001

Study locations (3)

• Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for HIV-associated cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07308886
  Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
  National Cancer Institute (NCI)
• RECRUITINGNANCT05561595
  Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
  University of Florida
• RECRUITINGPHASE1, PHASE2NCT06343311
  T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
  Estrella Biopharma, Inc.
• ACTIVE NOT RECRUITINGNCT06480773
  Kaposi Sarcoma Chemotherapy and Research (KS-CARE)
  UNC Lineberger Comprehensive Cancer Center
• RECRUITINGPHASE1NCT04902443
  Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT04941274
  Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
  National Cancer Institute (NCI)

See all trials for HIV-associated cancer →